Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI

Children with osteogenesis imperfecta (OI) type VI often have high fracture rates despite the current standard treatment with bisphosphonates. Subcutaneous injections of denosumab have been proposed as an alternative treatment approach, but safety data on denosumab in children are limited. Here we d...

Descripción completa

Detalles Bibliográficos
Autores principales: Trejo, Pamela, Rauch, Frank, Ward, Leanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Society of Musculoskeletal and Neuronal Interactions 2018
Materias:
Case Report Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881132/
https://www.ncbi.nlm.nih.gov/pubmed/29504582

Ejemplares similares

Ejemplares similares